TAT-10: Directing Alpha-emitting Conjugates to Cancer Chromatin via PARP-1
IMR-05, SK-N-SH and NLF were the most sensitive cell line whereas Be-2-c was the most resistant. At211-MM4 therapy showed significant DNA damage as measured by gH2AX. Interestingly therapy caused the most resistant cell line Be-2-c to increase PARP-1 expression. As expected, IMR-05 results in vitro translated into the highest therapeutic efficacy in in vivo models.
Presented By: Mehran Makvandi from University of Pennsylvania Perelman School of Medicine, Department of Radiology and Division of Nuclear Medicine
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.